Ocean Biomedical announces findings in EGFR-mutant lung cancer
Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...
Medindia23h
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
("BioRay") announced thatNMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 for injection. BR111 is an antibody-drug ...